What happened with INMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
InMode Ltd. supplies physicians with equipment for procedures such as fat reduction, face and body contouring, and skin tightening. Its products use radio-frequency energy to heat tissue, with both minimally invasive and non-invasive treatments. BodyTite and IgniteRF are among its platforms. Equipment sales generate most revenue, and minimally invasive products account for the largest share of the business.
Physicians buy through InMode’s direct sales teams or independent distributors. They can add treatment applicators to existing platforms, and applicable procedures require disposable handpieces or tips that must be replaced after each treatment. These consumables and extended warranties provide a smaller revenue stream after the initial equipment sale. Demand depends on physicians’ willingness and ability to finance equipment purchases, which in turn depends on patients choosing mostly elective treatments that insurance generally does not cover.
InMode outsources almost all manufacturing to subcontractors in Israel and relies heavily on Flextronics (Israel) Ltd. and BY Medimor Ltd. Its ability to supply equipment therefore depends on these manufacturers. Device authorizations also constrain what it can sell and promote: products marketed in the United States that require FDA authorization have 510(k) clearance for their marketed uses, while new uses or significant changes may require further authorization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
InMode's results hinge on demand for elective aesthetic procedures and physicians' access to equipment financing, with competition also coming from device makers absent here: Sofwave, Sisram Medical, Cynosure and BTL Aesthetics.
Apyx Medical Corporation competes for the cosmetic surgeons who buy InMode's minimally invasive body-contouring and tissue-tightening equipment, selling them Renuvion energy-based surgical systems. Watch its Renuvion business for competition within this shared surgeon customer base.
Evolus, Inc. competes for patients who can choose injections instead of InMode's wrinkle-reduction and skin-tightening procedures, selling aesthetic practitioners neurotoxins and hyaluronic-acid fillers for self-paying patients. Its Jeuveau and Evolysse sales offer a view of spending on these injectable alternatives.
SBC Medical Group Holdings Incorporated shares InMode's exposure to patient demand for cosmetic procedures, but earns fees from supporting Japanese aesthetic clinics rather than selling equipment and treatment consumables. Its clinic-management service revenue offers a separate view of the same elective spending demand.
AbbVie competes with some InMode equipment-based aesthetic treatments by selling Botox as an alternative. Watch Botox rather than AbbVie's overall results, which also reflect its much broader medicines business.
Evolus, Inc. earningsEOLS
Evolus's report will show how spending on injectable aesthetics is changing, where its treatments compete with some of InMode's skin-tightening and wrinkle-reduction procedures.
Watch sales of Evolus's Jeuveau and Evolysse. Stronger sales would show that patients are still paying for elective injectables, while confirming that these treatments compete for some of the same spending as InMode procedures. Weaker sales could mean less pressure from this injectable alternative, but would not prove patients are switching to InMode. The takeaway is how injectable demand is weighing against demand for InMode's device-based treatments, not that the treatments are interchangeable.
Apyx Medical Corporation earningsAPYX
Apyx Medical's report will show whether cosmetic surgeons are buying its Renuvion energy-based systems, which compete with InMode's minimally invasive contouring and tissue-tightening equipment.
Watch the Renuvion business. Stronger sales would show that cosmetic surgeons are still buying energy-based surgical systems: a sign of category demand, but also of active competition for InMode. Weaker sales could reflect tighter equipment spending among shared surgeon customers; it would not, on its own, mean InMode won those orders. Read it alongside InMode's own platform sales to distinguish soft equipment demand from stronger competition.
InMode Ltd. earningsThis company
InMode's report will show whether newer non-invasive platforms can offset softer demand for minimally invasive platforms while sales of consumables from its installed base hold up.
Read sales of non-invasive platforms alongside minimally invasive platforms, then check whether consumables revenue is holding up. Growth in non-invasive platforms, steadier minimally invasive sales and resilient consumables would suggest newer products are adding demand while existing systems continue to generate follow-on sales. If non-invasive sales rise while the other two weaken, the mix is shifting rather than demand broadly recovering. That distinction shows whether new products are truly making up for weakness in established platforms.
